The European Medicines Agency (EMA) grants marketing authorization for the first coronary vaccine in the EU.

The mother decided on a marketing authorization on Monday.

“This is a significant step forward in the fight against the corona,” Emma Cooke, Emma’s director, said at the news conference.

Cooke says the coronary vaccine is a historic achievement.

The vaccine was developed in one year.

The work has been done night and day.

The first coronary vaccine is developed by Pfizer and Biontech.

Cooke said the first coronary vaccine also works against a new variant of the virus.

Next, the marketing authorization for the vaccine will be approved by the European Commission.

European Commission President Ursula von der Leyen says on Twitter that she is awaiting a decision from the Commission on a marketing authorization for the coronary vaccine today.

According to Von der Leyen’s tweet, we now need to act quickly.

He describes the decision of the European Medicines Agency to be a crucial moment in the efforts to make safe and effective coronary vaccines available to Europeans.

Deliveries of medicines to Finland and EU countries can only start when the vaccine has a marketing authorization.

The aim is to start vaccinations at the same time in all EU countries.

Vaccines are expected to arrive in Finland during Christmas.

The first vaccinations may begin on Sunday, December 27th.

Tuija Kumpulainen, Head of Department at the Ministry of Social Affairs and Health, has told the public that about 10,000 vaccine doses will arrive in Finland in the first batch.

Two doses are needed, so the first batch can vaccinate 5,000 people.

The story was updated throughout at 4:21 p.m.